XML 61 R38.htm IDEA: XBRL DOCUMENT v3.23.1
Segment Disclosures (Tables)
 3 Months Ended
Mar. 31, 2023
Segment Reporting [Abstract]  
Summary of Financial Information of Reportable Segments
The following tables summarize information for the reportable segments (in thousands):
For the three months ended March 31, 2023:
Life ScienceMedical OfficeCCRCOther Non-reportableCorporate Non-segmentTotal
Total revenues$205,464 $186,967 $127,084 $6,163 $— $525,678 
Government grant income(1)
— — 137 — — 137 
Less: Interest income— — — (6,163)— (6,163)
Healthpeak’s share of unconsolidated joint venture total revenues2,165 745 — 20,346 — 23,256 
Healthpeak’s share of unconsolidated joint venture government grant income— — — 228 — 228 
Noncontrolling interests’ share of consolidated joint venture total revenues(143)(8,963)— — — (9,106)
Operating expenses(57,566)(64,398)(101,124)— — (223,088)
Healthpeak’s share of unconsolidated joint venture operating expenses(1,182)(305)— (15,006)— (16,493)
Noncontrolling interests’ share of consolidated joint venture operating expenses40 2,595 — — — 2,635 
Adjustments to NOI(2)
(832)(3,821)50 (21)— (4,624)
Adjusted NOI147,946 112,820 26,147 5,547 — 292,460 
Plus: Adjustments to NOI(2)
832 3,821 (50)21 — 4,624 
Interest income— — — 6,163 — 6,163 
Interest expense— (1,920)(1,816)— (44,227)(47,963)
Depreciation and amortization(75,582)(71,158)(32,485)— — (179,225)
General and administrative— — — — (24,547)(24,547)
Transaction costs(158)(132)(219)— (1,916)(2,425)
Impairments and loan loss reserves, net— — — 2,213 — 2,213 
Gain (loss) on sales of real estate, net60,498 21,312 — (232)— 81,578 
Other income (expense), net4 204 (667)— 1,231 772 
Less: Government grant income— — (137)— — (137)
Less: Healthpeak’s share of unconsolidated joint venture NOI(983)(440)— (5,568)— (6,991)
Plus: Noncontrolling interests’ share of consolidated joint venture NOI103 6,368 — — — 6,471 
Income (loss) before income taxes and equity income (loss) from unconsolidated joint ventures132,660 70,875 (9,227)8,144 (69,459)132,993 
Income tax benefit (expense)— — — — (302)(302)
Equity income (loss) from unconsolidated joint ventures598 189 — 1,029 — 1,816 
Income (loss) from continuing operations133,258 71,064 (9,227)9,173 (69,761)134,507 
Income (loss) from discontinued operations— — — — — — 
Net income (loss)$133,258 $71,064 $(9,227)$9,173 $(69,761)$134,507 
______________________________________________________________________________
(1)Represents government grant income received under the CARES Act, which is recorded in other income (expense), net in the Consolidated Statements of Operations (see Note 2).
(2)Represents straight-line rents, amortization of market lease intangibles, net, actuarial reserves for insurance claims that have been incurred but not reported, deferral of community fees, and termination fees. Includes the Company’s share of income (loss) generated by unconsolidated joint ventures and excludes noncontrolling interests’ share of income (loss) generated by consolidated joint ventures.
For the three months ended March 31, 2022:
 Life ScienceMedical OfficeCCRCOther Non-reportableCorporate Non-segmentTotal
Total revenues$194,055 $177,263 $121,560 $5,494 $— $498,372 
Government grant income(1)
— — 6,552 — — 6,552 
Less: Interest income— — — (5,494)— (5,494)
Healthpeak’s share of unconsolidated joint venture total revenues1,431 732 — 18,045 — 20,208 
Healthpeak’s share of unconsolidated joint venture government grant income— — 333 315 — 648 
Noncontrolling interests’ share of consolidated joint venture total revenues(57)(8,820)— — — (8,877)
Operating expenses(48,189)(61,170)(97,888)— — (207,247)
Healthpeak’s share of unconsolidated joint venture operating expenses(483)(299)— (14,055)— (14,837)
Noncontrolling interests’ share of consolidated joint venture operating expenses19 2,602 — — — 2,621 
Adjustments to NOI(2)
(14,112)(3,546)— (8)— (17,666)
Adjusted NOI132,664 106,762 30,557 4,297 — 274,280 
Plus: Adjustments to NOI(2)
14,112 3,546 — 8 — 17,666 
Interest income— — — 5,494 — 5,494 
Interest expense— (1,036)(1,865)— (34,685)(37,586)
Depreciation and amortization(78,138)(67,773)(31,822)— — (177,733)
General and administrative— — — — (23,831)(23,831)
Transaction costs(292)(4)— — — (296)
Impairments and loan loss reserves, net— — — (132)— (132)
Gain (loss) on sales of real estate, net3,856 — — — — 3,856 
Other income (expense), net(9)10,937 6,511 (32)909 18,316 
Less: Government grant income— — (6,552)— — (6,552)
Less: Healthpeak’s share of unconsolidated joint venture NOI(948)(433)(333)(4,305)— (6,019)
Plus: Noncontrolling interests’ share of consolidated joint venture NOI38 6,218 — — — 6,256 
Income (loss) before income taxes and equity income (loss) from unconsolidated joint ventures71,283 58,217 (3,504)5,330 (57,607)73,719 
Income tax benefit (expense)— — — — (777)(777)
Equity income (loss) from unconsolidated joint ventures966 200 539 379 — 2,084 
Income (loss) from continuing operations72,249 58,417 (2,965)5,709 (58,384)75,026 
Income (loss) from discontinued operations— — — — 317 317 
Net income (loss)$72,249 $58,417 $(2,965)$5,709 $(58,067)$75,343 
______________________________________________________________________________
(1)Represents government grant income received under the CARES Act, which is recorded in other income (expense), net in the Consolidated Statements of Operations (see Note 2).
(2)Represents straight-line rents, DFL non-cash interest, amortization of market lease intangibles, net, actuarial reserves for insurance claims that have been incurred but not reported, deferral of community fees, and termination fees. Includes the Company’s share of income (loss) generated by unconsolidated joint ventures and excludes noncontrolling interests’ share of income (loss) generated by consolidated joint ventures.